1

SPONSORED SYMPOSIUM

2

SalaSinopoli

TeatroStudio

08.00 - 09.00TEVA SYMPOSIUMNon CME Session

10.00 - 11.00ELI-LILLY SYMPOSIUM

Non CME Session

14.30 - 15.30CEFALY TECHNOLOGY SYMPOSIUM

Non CME Session

SalaSinopoli

08.00 - 09.00NOVARTIS SYMPOSIUM

Non CME Session

11.30 - 12.30ALLERGAN SYMPOSIUM

Non CME Session

TimetableFriday, 1 December 2017

TimetableSaturday, 2 December 2017

3

Friday, 1 December 2017

Sala Sinopoli

08:00 - 09:00 TEVA SYMPOSIUM - Non CME Session

CGRP IN MIGRAINE PREVENTION: IMPACT, RATIONALE, AND IMPLICATIONS

Symposium Chairman: Professor Paolo Martelletti, MD, PhD

Speakers and Specific Subtitles:

Messoud Ashina, MD, PhD: Public Health Impact of Migraine in Europe

Cristina Tassorelli, MD, PhD: Appropriate Patients for Migraine

Prevention and Issues with Persistence and Adherence on Current Standard of Care

Rami Burstein, PhD: CGRP and Migraine Pathophysiology

Teatro Studio

10:00 - 11:00 ELI-LILLY SYMPOSIUM - Non CME Session

A TARGETED APPROACH TO MIGRAINE

10.00 - 10.10 Welcome and introduction - Paolo Martelletti MD (Italy)

10.10 - 10.30 Do we need any more treatments for acute migraine? - Antoinette Maassen van den

Brink, PhD (The Netherlands)

10.30 - 10.50 A targeted approach to preventing migraines and the elevated expectations

on response rates - Patricia Pozo-Rosich, MD, Phd (Spain)

10.50 - 11.00 Panel discussion and questions and answers, closing remarks - All

14:30 - 15:30 CEFALY TECHNOLOGY SYMPOSIUM - Non CME Session

E-TNS IN THE TREATMENT OF MIGRAINE

14.30 - 14.40 Introduction: rational, technology and parameters (Stephen Silberstein)

14.40 - 14.55 Efficacy in migraine prevention (Antonio Russo)

14.55 - 15.10 Efficacy in migraine attack treatment (Jean Schoenen)

15.10 - 15.20 Mechanisms of action (Gianluca Coppola)

15.20 - 15:30 Q&A -

Chairman: Marina de Tommaso

Moderator: Paolo Martelletti

4

Saturday, 2 December 2017

Sala Sinopoli

08:00 - 09:00 NOVARTIS SYMPOSIUM - Non CME Session

TARGETING MIGRAINE BY DESIGN – NEW TREATMENT APPROACHES TO SHAPE FUTURE PATIENT CARE

Chair: Andreas Gantenbein (RehaClinic, Bad Zurzach, Switzerland)

08.00 - 08.05 Welcome and introduction

08.05 - 08.20 Is there a need for new prophylactic treatments of migraine? (Interactive debate)

Moderator: Andreas Gantenbein (RehaClinic, Bad Zurzach, Switzerland)

08.20 - 08.35 Rethinking migraine management - Cristina Tassorelli (Università degli Studi di Pavia, Italy)

08.35 - 08.50 Targeting the underlying biology of migraine - Lars Edvinsson (Lund University, Sweden)

08:50 – 09.00 Closing remarks - Andreas Gantenbein (RehaClinic, Bad Zurzach, Switzerland)

11:30 - 12:30 ALLERGAN SYMPOSIUM - Non CME Session

BOTULINUM TOXIN TYPE A: NEW INSIGHTS INTO TREATMENT OF CHRONIC MIGRAINE FROM EMERGING DATA.

Chair: Paolo Martelletti (Italy)

11.30 - 11.40 Welcome and introductions

Overview of most recent real world data - Paolo Martelletti, Italy

11.40 - 12.00 Understanding chronic migraine: the pathophysiology and how botulinum toxin type

A works to help relieve the burden of this condition - Rami Burstein, US

12.00 - 12.25 The FORWARD study: results of a head-to-head comparison of botulinum toxin type

A versus topiramate for the treatment of chronic migraine - Andrew Blumenfeld, US

12.25 - 12.30 Wrap-up and closing